Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: The Company develops noninvasive diagnostics for early-stage lung cancer (CyPath® Lung) using flow cytometry and AI. It operates through two segments: Diagnostic R&D and Laboratory Services (via subsidiary Precision Pathology Laboratory Services, LLC). The Company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $1,351,527 | $1,853,597 |
| Net Loss | $(3,630,610) | $(2,660,417) |
| Loss Per Share (Basic & Diluted) | $(0.81) | $(4.80) |
| Cash and Cash Equivalents (End of Period) | $3,098,366 | $444,706 |
| Accumulated Deficit | $(72,184,674) | $(56,304,727) |
| Working Capital | $1,156,441 | $4,659,042 |
| Total Debt (Notes & Leases) | $836,371 | $N/A (Not explicitly aggregated in text) |
Note: Working Capital calculated as Total Current Assets ($4,341,401) minus Total Current Liabilities ($3,184,960).
Material Changes vs. Prior Period
- Revenue Decline: Consolidated revenue decreased 27% to $1.35 million, primarily due to the discontinuation of certain unprofitable pathology services in March 2025. This was partially offset by a 114% increase in CyPath® Lung testing revenue ($361,000 vs. $169,000).
- Increased Operating Loss: Net loss widened by approximately $970,000 year-over-year. Operating expenses increased 11% to $4.97 million.
- Expense Drivers:
- Clinical Development: Increased 141% to $334,040 due to the initiation of a pivotal clinical trial.
- Selling, General & Administrative (SG&A): Increased 32% to $3.24 million, driven by added personnel to support sales growth.
- Direct Costs: Decreased 32% to $928,636 following strategic cost-reduction actions in the prior year.
- Cash Flow: Net cash used in operating activities increased to $3.23 million (from $1.64 million), reflecting the higher operating loss and increased accounts receivable.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months. Cash on hand ($3.1 million) is projected to support operations only through June 2026.
- Capital Needs: The Company must raise additional capital through equity, debt, or strategic partnerships to fund operations and clinical trials. Failure to do so may result in curtailment of operations.
- Unusual Item (Accounting Correction): The Company recorded an out-of-period adjustment of approximately $336,000 to Operating lease right-of-use assets and liabilities, and an expense of $28,000, to correct an error related to a lease amendment executed in April 2024.
- Outlook: Unit sales for CyPath® Lung grew 146% in Q1 2026. The Company enrolled its first patient in a pivotal clinical trial in March 2026.
- Risks: Dependence on third-party funding, regulatory approval uncertainties, and potential delisting from Nasdaq if listing standards are not met.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for the next capital raise given the "substantial doubt" disclosure and cash runway extending only to June 2026.
- Revenue Quality: Assess the sustainability of the 114% growth in CyPath® Lung revenue versus the decline in general pathology services.
- Clinical Trial Progress: Monitor the enrollment and results of the pivotal clinical trial (NCT07168993) which drove the spike in clinical development expenses.
- Debt Obligations: Review the terms of outstanding notes payable and finance leases, particularly the vehicle loans and D&O insurance financing.
- Stock Dilution: Note the existence of 1.35 million outstanding warrants and 101,448 shares of convertible preferred stock that could dilute existing shareholders upon exercise or conversion.